What are the indications for Cabergoline?

Cabergoline is a dopamine receptor agonist widely used clinically. Its main mechanism of action is to inhibit the secretion of prolactin in the anterior pituitary gland by stimulating D2 receptors. Hyperprolactinemia (HPRL) is a type of endocrine disease, often caused by pituitary prolactin adenoma or other pathological factors. Patients often present with symptoms such as oligomenorrhea, amenorrhea, infertility, galactorrhea, and hypogonadism.

In male patients, loss of libido, erectile dysfunction, and even infertility may also occur. The emergence of cabergoline provides these patients with a relatively safe and effective treatment option. According to the instructions, the main indications for this product include idiopathic hyperprolactinemia, hyperprolactinemia caused by pituitary adenoma, and other causes of elevated serum prolactin levels. It not only reduces serum prolactin levels but also restores ovulatory function and normal menstrual cycles, so it has clinical value in the auxiliary treatment of female infertility.

Judging from the application trends of overseas research and clinical guidelines, cabergoline has a long half-life and only needs to be taken once or twice a week Compared with traditional drugs such as bromocriptine, it has better compliance and easier to tolerate side effects, so it has gradually become a first-line treatment drug. In patients with pituitary microadenoma or macroadenoma, long-term standardized use of cabergoline can effectively reduce the size of the tumor. In some cases, the tumor can even be significantly reduced or completely disappeared, reducing the compression of the optic nerve and improving the patient's quality of life.

In addition, cabergoline has also been explored in some guidelines for the treatment of diseases such as Parkinson's disease, but such indications have not yet been approved in most countries. Overall, the main indications of cabergoline focus on the treatment of hyperprolactinemia, especially in patient groups caused by pituitary prolactinoma or idiopathic factors, and it occupies an important position in the fields of endocrinology and reproductive medicine.

Reference materials:https://www.drugs.com/mtm/cabergoline.html